Linked Life Data

10699324

Source:http://linkedlifedata.com/resource/pubmed/id/10699324

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
17
pubmed:dateCreated
2000-4-13
pubmed:abstractText
The safety and immunogenicity of the live attenuated cold-passaged, temperature-sensitive (cpts) 248/404 respiratory syncytial virus (RSV) A2 and the RSV A2 purified F glycoprotein (PFP-2) vaccine candidates were evaluated in a placebo-controlled trial in 60 healthy young adults and 60 healthy elderly subjects using simultaneous and sequential (cpts 248/404 followed by PFP-2) vaccination schedules. Both vaccines were well tolerated. The cpts 248/404 vaccine was moderately infectious in both young and old volunteers, but was highly restricted in replication in those who were infected. After both vaccines, RSV neutralizing antibody (neut Ab) titers increased fourfold in 22% of young subjects and in 16% of elderly subjects. Of those with low levels of RSV neut Ab (titer <9), 10/12 (83% of) young subjects and six/eight (75% of) elderly subjects had a >/=four fold rise in neut Ab titer. Young and elderly subjects immunized simultaneously had similar serum IgG and IgA postimmunization titers to RSV F (IgG, 16.4 vs 16.2, IgA 11.6 vs 12. 5, respectively) as did those who were immunized sequentially (IgG 17.4 vs 17.0, IgA 13.0 vs 13.5). In both age groups, sequential immunization elicited higher postimmunization RSV F IgG and IgA titers than simultaneous immunization. Further studies that combine the PFP-2 subunit vaccine with a less attenuated RSV vaccine should be performed.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
6
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1763-72
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:10699324-Adolescent, pubmed-meshheading:10699324-Adult, pubmed-meshheading:10699324-Aged, pubmed-meshheading:10699324-Aged, 80 and over, pubmed-meshheading:10699324-Antibodies, Viral, pubmed-meshheading:10699324-Antibody Formation, pubmed-meshheading:10699324-Dose-Response Relationship, Immunologic, pubmed-meshheading:10699324-Drug Administration Schedule, pubmed-meshheading:10699324-Female, pubmed-meshheading:10699324-HN Protein, pubmed-meshheading:10699324-Humans, pubmed-meshheading:10699324-Immunity, Mucosal, pubmed-meshheading:10699324-Immunoglobulin A, pubmed-meshheading:10699324-Immunoglobulin G, pubmed-meshheading:10699324-Male, pubmed-meshheading:10699324-Middle Aged, pubmed-meshheading:10699324-Nasal Mucosa, pubmed-meshheading:10699324-Regression Analysis, pubmed-meshheading:10699324-Respiratory Syncytial Virus, Human, pubmed-meshheading:10699324-Vaccines, Attenuated, pubmed-meshheading:10699324-Viral Envelope Proteins, pubmed-meshheading:10699324-Viral Proteins, pubmed-meshheading:10699324-Viral Vaccines
pubmed:year
2000
pubmed:articleTitle
Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults.
pubmed:affiliation
Division of Disease Control, Department of International Health, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD 21205, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial